X0206 3 2017-06-28 0 0001420565 AILERON THERAPEUTICS INC ALRN 0001681884 LV Management Group, LLC 115 WEST WASHINGTON STREET SUITE 1680-SOUTH INDIANAPOLIS IN 46204 0 0 1 0 0001575852 Lilly Ventures Fund I LLC 115 WEST WASHINGTON STREET SUITE 1680-SOUTH INDIANOPOLIS IN 46204 0 0 1 0 0001552293 Torres S. Edward C/O LILLY VENTURES 115 WEST WASHINGTON STREET, SUITE 1680-S INDIANAPOLIS IN 46204 0 0 1 0 0001602732 Hall Steven Edward C/O LILLY VENTURES 115 WEST WASHINGTON STREET, SUITE 1680-S INDIANAPOLIS IN 46204 0 0 1 0 Series D Preferred Stock Common Stock 341238 I By Fund Series E-2 Preferred Stock Common Stock 191946 I By Fund Series E-3 Preferred Stock Common Stock 166489 I By Fund Series F Preferred Stock Common Stock 145312 I By Fund The Series D Preferred Stock is convertible into Common Stock on a 9.937-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. The Series E-2 Preferred Stock is convertible into Common Stock on a 9.937-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. The Series E-3 Preferred Stock is convertible into Common Stock on a 9.937-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. The Series F Preferred Stock is convertible into Common Stock on a 9.937-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which consists of Ed Torres, Dr. Steve Hall and Armen B. Shanafelt. Each of the individuals and entities listed above expressly disclaims beneficial ownership of the shares held by LVFI, except to the extent of his or its pecuniary interest therein. Dr. Shanafelt is a director of the Issuer and, accordingly, files separate Section 16 reports. /s/ S. Edward Torres, LV Management Group, LLC 2017-06-28 /s/ S. Edward Torres, Lilly Ventures Fund I, LLC 2017-06-28 /s/ S. Edward Torres 2017-06-28 /s/ Steven Edward Hall 2017-06-28